|
- OPTIMAX (0222) Overview - OPTIMAX HOLDINGS BERHAD | I3investor
Optimax Holdings Sdn Bhd is a Malaysia-based company, which provides eye specialist services The Company offers a range of services in medical ophthalmology at its specialist centers The Company provides treatments relating to eye and vision difficulties or impairment covering refractive error, cataract, glaucoma, macular degeneration, diabetic retinopathy and other eye diseases and
- Optimax Holdings Berhad - Strategic Regional Expansions
Optimax Holdings is strategically expanding its operations in Malaysia and Southeast Asia, focusing on patient volume growth and medical tourism, with a target price of RM0 83
- OPTIMAX Announces Interim Dividend of 0. 80 Sen, Consistent with . . .
OPTIMAX announces an interim dividend of 0 80 sen, reflecting a positive trend in shareholder returns Read more for details
- OPTIMAX (0222): OPTIMAX HOLDINGS BERHAD IPO Info | I3investor
阿笔股票观察名单系列6-浅谈Optimax Holdings Berhad 拓展版图，进军东南亚及医美市场 Optimax稳健的盈利能力和近19%的股本回报率，显示其良好的运营效率与资本运用能力。
- OPTIMAX HOLDINGS BERHAD Submits Annual Report for 2024
OPTIMAX HOLDINGS BERHAD has officially announced the submission of its annual report for the financial year ended 31 December 2024 This announcement was made on 29 April 2025, categorized under document submission The annual report is a critical document that outlines the company's financial performance and governance practices over the past
- OPTIMAX HOLDINGS BERHAD Announces Q2 FY2025 Financial Results
Company announcement: OPTIMAX: OPTIMAX HOLDINGS BERHAD announces Q2 FY2025 financial results with increased revenue and profit, while declaring a proposed dividend of 0 00 sen per share
- OPTIMAX: OPTIMAX HOLDINGS BERHAD Reports Change in Substantial . . .
Company announcement: OPTIMAX: OPTIMAX HOLDINGS BERHAD reports a substantial shareholder change with SENA HOLDINGS acquiring 674,000 shares, increasing its stake to 29 73%
- Optimax: Sharpening Focus for a Clearer 2025? | I3investor
Optimax Holdings Bhd, after a period of blurred earnings and a 25% share price dip over the past year, is now eyeing a record profit in 2025 Key drivers are new ambulatory care centres (ACCs) and rising demand for premium eye procedures
|
|
|